Skip to main content Accessibility help
×
Home
Hostname: page-component-54cdcc668b-mnmn6 Total loading time: 0.217 Render date: 2021-03-08T17:28:58.303Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": false, "newCiteModal": false, "newCitedByModal": true }

Somatostatin analogues have no role in the treatment of advanced differentiated thyroid cancer

Published online by Cambridge University Press:  08 March 2006

O. Alhamarneh
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Hull Royal Infirmary, Hull, UK.
J. Murphy
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Hull Royal Infirmary, Hull, UK.
S.L. Atkin
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Hull Royal Infirmary, Hull, UK.
R.J.A. England
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Hull Royal Infirmary, Hull, UK.
Get access

Abstract

Somatostatins are neuropeptides that have a downregulatory effect on various physiological processes. Their use in the management of certain endocrine tumours is well recognized. Their use in thyroid cancer is not established, although there is some evidence to suggest that they have a role in advanced metastatic disease. We report a case of a patient with advanced metastatic follicular thyroid cancer which demonstrated strong octreotide uptake with reduced avidity for I131. Treatment with the somatostatin analogue octreotide, however, failed to achieve a significant response. We feel this case is important as it suggests that although octreotide provides a useful further imaging modality in differentiated thyroid cancer, it has no therapeutic role.

Type
Research Article
Copyright
© 2004 Royal Society of Medicine Press

Access options

Get access to the full version of this content by using one of the access options below.

Full text views

Full text views reflects PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.

Total number of HTML views: 0
Total number of PDF views: 7 *
View data table for this chart

* Views captured on Cambridge Core between September 2016 - 8th March 2021. This data will be updated every 24 hours.

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Somatostatin analogues have no role in the treatment of advanced differentiated thyroid cancer
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Somatostatin analogues have no role in the treatment of advanced differentiated thyroid cancer
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Somatostatin analogues have no role in the treatment of advanced differentiated thyroid cancer
Available formats
×
×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *